Triamcinolone acetonide aqueous (TAA AQ) and fluticasone propionate (FP) nasal sprays show equivalent relief of total symptom scores regardless of disease severity

Kaiser, Harold B.; Woodworth, Thomas H.; Liao, Yuning; Garcia, Jorge; Georges, George

doi:10.1016/s0091-6749(03)80758-3

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Berger et al [22] in 295 patients with symptomatic SAR, the mean ± SD change in the total nasal symptom score was equivalent between the study medications: –3.15 ± 0.19 with triamcinolone acetonide and –3.17 ± 0.18 with fluticasone propionate after 21 days of treatment. Similarly, Kaiser et al [21] found a mean change in the total symptom score of –4.84 with triamcinolone acetonide and –4.81 with fluticasone propionate in 150 patients with severe SAR who were treated for 3 weeks. Each of these prior studies administered intranasal triamcinolone acetonide at a daily dose of 220 µg and intranasal fluticasone propionate at a daily dose of 200 µg, which is in accordance with the dosages given in our study [20-23].…”

Section: Discussionmentioning

confidence: 94%

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Karaulov

Vylegzhanina

Овчинников

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Intranasal sprays are recommended as targeted therapy for allergic rhinitis (AR). Triamcinolone acetonide is a nasal corticosteroid preparation indicated for the treatment of seasonal and perennial AR (PAR) in different countries worldwide. Objectives: In order to determine the efficacy of triamcinolone acetonide in the treatment of PAR, the non-inferiority of triamcinolone acetonide to fluticasone propionate was assessed in Russian adults. Methods: In this randomized, double-blind, parallel-group, multicenter, prospective, non-inferiority, phase III clinical trial, a total of 260 patients with persistent PAR were randomized to receive either triamcinolone acetonide or fluticasone propionate nasal sprays for 4 weeks. The efficacy in symptom control was evaluated using the reflective total nasal symptom score (rTNSS) from baseline (day 0) to day 28. Safety was assessed through the reporting of adverse events. Results: The rTNSS mean values decreased from baseline to the end of study treatment (day 28) in both groups: –8.2 ± 3.0 in the triamcinolone acetonide arm versus –8.0 ± 2.8 in the fluticasone propionate arm. The mean difference between the groups (triamcinolone acetonide – fluticasone propionate) for rTNSS change from baseline was –0.2 (95% confidence interval –0.89 to 0.54), with an upper confidence limit of 0.54, which is lower than the non-inferiority margin of 0.8. Triamcinolone acetonide was well tolerated, with no difference in adverse event occurrence compared with fluticasone propionate. Conclusions: Triamcinolone acetonide proved to be non-inferior to fluticasone propionate in adult patients with PAR; both treatments decreased rTNSS values and showed a good safety profile.

show abstract

Section: Discussionmentioning

confidence: 94%

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Karaulov

Vylegzhanina

Овчинников

et al. 2019

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…The effects of aqueous triamcinolone acetonide (TAA AQ) and FP nasal sprays on HRQoL were investigated in a multi‐centre, investigator‐blinded, parallel‐group study (30). The trial involved 295 patients with SAR, who received once daily TAA AQ, 220 mg, or FP, 200 mg, for 3 weeks.…”

Section: Resultsmentioning

confidence: 99%

ARIA‐suggested drugs for allergic rhinitis: what impact on quality of life? A GA²LEN Review

Baiardini

Braido

Tarantini

et al. 2008

Allergy

View full text Add to dashboard Cite

Allergic diseases constitute a global health problem, as they have an increasing economic and social impact and, especially, they can deeply interfere with the patients’ daily life, being a cause of physical and emotional discomfort. This is why the health‐related quality‐of‐life (HRQoL) has become increasingly important in health care research; in fact, the assessment of the impact the disease and its treatment have on patients, provides a more comprehensive approach in outcome evaluation. Numerous validated questionnaires are available and many studies have been performed evaluating HRQoL in people affected by allergic rhinitis (AR), thus testifying a great interest in this topic. The aims of the present review are: to examine the scientific literature of the last 3 years dealing with the impact of AR treatments suggested by allergic rhinitis and its impact on asthma guidelines on patients’ QoL, and to identify the unexplored or not‐fully‐investigated areas concerning this issue.

show abstract

“…Recently, the data from this study were reanalyzed to evaluate whether symptom severity would affect the efficacy of TANS and FPNS. 30 Patients were stratified into two cohorts based on symptom sever-CHOOSING AN ALLERGIC RHINITIS THERAPY FOR CHILDREN 219 ity (moderate or severe). Both TANS and FPNS showed significant and comparable improvements in TNSS, individual symptom scores, and health-related quality of life scores.…”

Section: Comparative Efficacy Of Inssmentioning

confidence: 99%

“…Both TANS and FPNS showed significant and comparable improvements in TNSS, individual symptom scores, and health-related quality of life scores. 30 Mandl et al 23 conducted a 3-month, multicenter, double-blinded, double-dummy study in 548 patients 12 to 77 years of age with PAR who were randomized to receive MFNS 200 g once daily, FPNS 200 g once daily, or placebo. The primary efficacy variable was the mean change from baseline in total morning and evening patient-assessed nasal symptom scores over the first 15 days of treatment.…”

Section: Comparative Efficacy Of Inssmentioning

confidence: 99%

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Murphy¹

2005

Pediatric Asthma, Allergy & Immunology

View full text Add to dashboard Cite

Allergic rhinitis affects up to 40% of children in the United States. Proper management of this disease is important for controlling symptoms, improving quality of life, and preventing the development or exacerbation of comorbid diseases such as asthma, sinusitis, otitis media, and respiratory infections. Intranasal corticosteroids (INSs) are recognized as the most effective medication class for controlling allergic rhinitis symptoms and are recommended by guidelines as first-line treatment for moderate to severe cases of allergic rhinitis in patients of all ages. Four once-daily, aqueous formulations of INSs are available in the United States for pediatric patients: budesonide aqueous nasal spray (BANS), fluticasone propionate nasal spray (FPNS), mometasone furoate nasal spray (MFNS), and triamcinolone acetonide aqueous nasal spray (TANS). The results of comparative studies of these INSs show that all four appear to be similar in efficacy and tolerability. The sensory attributes of these INSs do differ and these differences may play a role in the choice of an INS for each patient. Based on studies in adults, patient preference was found to be greater for the sensory attributes of BANS and TANS than for those of FPNS and MFNS, although a number of patients still showed a preference for the attributes of FPNS and MFNS. Similar studies of INS sensory attributes have not been conducted in children. Prescribing the INS with sensory attributes most pleasing to the individual patient may be important in improving patient acceptance of and satisfaction with treatment and perhaps lead to better adherence with therapy. (Pediatr Asthma Allergy Immunol 2005; 18[4]:216-229.)Adapted from Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma.

show abstract

Triamcinolone acetonide aqueous (TAA AQ) and fluticasone propionate (FP) nasal sprays show equivalent relief of total symptom scores regardless of disease severity

Cited by 4 publications

References 0 publications

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

ARIA‐suggested drugs for allergic rhinitis: what impact on quality of life? A GA²LEN Review

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Contact Info

Product

Resources

About

Triamcinolone acetonide aqueous (TAA AQ) and fluticasone propionate (FP) nasal sprays show equivalent relief of total symptom scores regardless of disease severity

Cited by 4 publications

References 0 publications

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

Triamcinolone Acetonide versus Fluticasone Propionate in the Treatment of Perennial Allergic Rhinitis: A Randomized, Parallel-Group Trial

ARIA‐suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN Review

Allergic Rhinitis in Children: Selecting an Intranasal Corticosteroid

Contact Info

Product

Resources

About

ARIA‐suggested drugs for allergic rhinitis: what impact on quality of life? A GA²LEN Review